ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / XTLB / forecast
DRMA (34) NRSN (35) NCNA (46) MDCX (34) ⌘ Pro Terminal →

XTL Biopharmaceuticals Ltd. (XTLB) 12-Month Stock Forecast & Price Target Cone

$1.70 +5.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.71

XTL Biopharmaceuticals Ltd. (XTLB) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $4.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XTLB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XTLB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.70 (+5.60% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1016 tracked Health Care issuers, XTLB ranks #353 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XTLB compare to DRMA and NRSN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XTLB carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRMA (Dermata Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M) and NRSN (NeuroSense Therapeutics Ltd.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M). Among the 5-stock peer group, XTLB leads on earnings multiple (N/A) while DRMA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XTLB?
▼

For XTL Biopharmaceuticals Ltd. (XTLB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #353 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.71 (+0.82%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.3% Base Target
$6 Bull$2 Base$1 Bear
📬 FREE XTLB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XTLB)Realized 20D OHLCV Swing Band: ±12.4%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY XTLB SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($110.8K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$1.98-2% Next Q
Q2 (-2Q)
51
Grade C-$1.94-6.7% Next Q
Q3 (-1Q)
49
Grade D$1.81-6.1% Next Q
Current
46
Grade D$1.70-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XTLB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XTLB currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.19) and Max Pain ($1.79) forces dealer call-delta covering toward $5.92.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XTLB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XTLB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your XTLB Position Size: $10,000

Shares at $1.70: 5882.4 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.26
$7,412
$-2,588 (-25.9%)
12M Consensus BaseTarget $1.61
$9,471
$-529 (-5.3%)
12M Bull Case BreakoutTarget $5.92
$34,824
+$24,824 (+248.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$669%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XTLB)

  • ✓Walkthrough of XTLB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
XTLB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.50%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.76H $1.76L $1.61C $1.70VOL 8.6K
RES: $3.68SUP: $1.56SMA50: $2.19SMA200: $2.68
$4.18$3.48$2.78$2.08$1.38RES $3.68SUP $1.56$1.702026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XTLB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XTLB Butterfly Map → + Track XTLB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on XTLB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XTLB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XTLB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XTLB)

Health Care Rank #353 of 1016 ⚔️ DRMA vs XTLB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XTLB vs. DRMA, NRSN, NCNA, MDCX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, XTL Biopharmaceuticals Ltd. (XTLB) ranks #353 by composite RQD confidence (46/100, grade D) and #957 by equity capitalization ($4.0M). Within this direct 5-issuer industry benchmark cohort, XTLB leads on earnings valuation at N/A trailing P/E, while DRMA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. XTLB currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XTLB ACTIVE
XTL Biopharmaceuticals Ltd.
D 46/100 — — — +5.60% $4.0M Benchmark Subject
DRMA
Dermata Therapeutics Inc.
E 34/100 — — -35.0% -2.73% $3.8M /drma-vs-xtlb →
NRSN
NeuroSense Therapeutics Ltd.
D- 35/100 — — -35.0% -28.14% $3.8M /nrsn-vs-xtlb →
NCNA
NuCana plc
D 46/100 — — — -2.96% $4.2M /ncna-vs-xtlb →
MDCX
Medicus Pharma Ltd.
E 34/100 — — -35.0% +2.66% $3.6M /mdcx-vs-xtlb →

2. XTLB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

XTL Biopharmaceuticals Ltd. (XTLB) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $4.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. XTLB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XTLB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $1.70 (+5.60% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1016 tracked Health Care issuers, XTLB ranks #353 in composite RQD confidence.

How does XTLB compare to DRMA and NRSN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XTLB carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DRMA (Dermata Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M) and NRSN (NeuroSense Therapeutics Ltd.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $3.8M). Among the 5-stock peer group, XTLB leads on earnings multiple (N/A) while DRMA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XTLB?

For XTL Biopharmaceuticals Ltd. (XTLB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #353 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XTLB trading relative to its 50-day, 200-day, and 52-week technical levels?

XTLB last traded at $1.70 (+5.60% on volume of 12,984 shares), positioning the stock -22.37% below its 50-day simple moving average ($2.19) and -36.57% below its 200-day simple moving average ($2.68). Across its 52-week range of $1.60 to $5.64, XTLB sits at the 2.5% percentile with a 14-day RSI of 36.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.4% ($1.49 to $1.91).

Direct Sub-Reports: XTLB RQD Cockpit XTLB 12M Forecast XTLB Earnings & Move XTLB Dividends & DRIP XTLB Insiders & 13F XTLB Whale Options XTLB Profit Sankey XTLB News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

XTLB — XTL Biopharmaceuticals Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

XTL Biopharmaceuticals Ltd. (XTLB) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.70 (+5.60% 1D, market capitalization $4.0M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (XTLB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.60 – $5.64 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links and no proprietary signals recorded. Sector correlations and 2nd-order bottlenecks cannot be identified from the source data.

  • Key Question #1: Can XTLB sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $5.64 52-week high?
  • Key Question #3: How sensitive is XTLB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

XTLB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for XTL Biopharmaceuticals Ltd. (XTLB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XTLB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XTLB Bull vs. Bear Conversation Board — What's Your Call at $1.70?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XTLB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on XTLB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.98 (+23.0%)
📌 Pinned Debate

Per the RQD rating, a moderate Forensic Balance Sheet score of 13/20 (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) suggests the comp

The street is overcomplicating XTL Biopharmaceuticals Ltd. (XTLB). Per the RQD rating, a moderate Forensic Balance Sheet score of 13/20 (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) suggests the company is not in distress on leverage metrics.. With an RQD score of 46/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.74.

CapAlloc_Nerd 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.26 (-21.7%)
Spot @ $1.61

Per the RQD rating, Whale 13F Flow scores only 3/20 and FCF yield and ROIC are both 0%, indicating weak institutional support and no re

I respect the product at XTL Biopharmaceuticals Ltd., but the stock at $1.61 is a different story. Per the RQD rating, Whale 13F Flow scores only 3/20 and FCF yield and ROIC are both 0%, indicating weak institutional support and no reported cash generation.. FCF yield is 0.0% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%